Biothera has posted top-line results from its Phase IIb clinical trial in non-small cell lung cancer (NSCLC) that evaluated its immunotherapeutic drug candidate, Imprime PGG, with cetuximab (Erbitux), carboplatin and paclitaxel compared with the monoclonal antibody and chemotherapy combination alone. Full data will be released at an upcoming scientific meeting. The primary endpoint of the open label, multicenter, randomized trial in 90 patients with untreated advanced NSCLC was objective respon...